Oxford COVID Vaccine Safe, Effective, Especially in Older Adults

Henrietta Strickland
November 22, 2020

Now, after completing a phase three study, the vaccine has proven to be 95 percent effective with "no serious safety concerns observed" in the trial participants.

"Our vaccine, therefore, costs about the same as a flu shot, which is between Dollars 10 and USD 50", he was quoted as saying.

Now, it looks like the company is open to the idea of selling this vaccine to governments around the world.

"While we can not predict how long the FDA's review will take, the FDA will review the request as expeditiously as possible", FDA Commissioner Stephen Hahn said in a statement. There are now no licensed mRNA vaccines.

The submission to the FDA is based on results from the Phase 3 clinical trial of Pfizer's vaccine, which began in the United States on July 27 and enrolled more than 43,000 volunteers. This corresponds to an efficacy of 94.5%.

India is also in talks with Moderna to cater to its mass requirement of vaccine shots for the 1.3 billion population.

It said: "Further assessment of the efficacy of this vaccine is warranted in all age groups and individuals with comorbidities (the presence of one or more conditions in a person at the same time)".

Commenting on the recent development in the vaccine, he said: "Filing for emergency use authorization in the USA is a critical step in making our vaccine candidate available to the global population as quickly as possible". And why do they need to be kept so cold? "As a result, it is crucial that Covid-19 vaccines are tested in this group who are also a priority group for immunisation".

"Initial results [are] expected in 4 to 6 months".

Separately, Pfizer's chief executive Albert Bourla said on Tuesday that the firm plans to submit its vaccine data to the US Food and Drug Administration for emergency-use authorisation.

A key researcher at the university says this is important because vaccines often don't work as well in older people.

Sinopharm has yet to comment which vaccines were used in the emergency program and Jingzhen was unclear about which vaccine he was addressing. In addition to that, 30 million doses may be available in January and 35 million more in the next two months. The longevity of the vaccines' immunity are also up for debate.

This is significantly lower than the standard 2-8 degrees Celsius storage requirement.

Sinopharm is testing two vaccines in late-stage trials in countries including the UAE, Bahrain, Egypt, Jordan, Peru, and Argentina.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER